Table XXXII.

Recommendations on treatment of lipid disorders in patients with chronic kidney disease

Recommendation	Class	Level
Patients with chronic kidney disease are at very high (those with eGFR < 30 ml/min/1.73 m2) or high (eGFR 30–60 ml/min/1.73 m2) cardiovascular risk.	I	A
In patients not requiring dialysis therapy, intensive lipid-lowering therapy is recommended, with a statin in the first line, followed by a combination of a statin with ezetimibe.	I	A
In patients not requiring dialysis therapy, combination with a PCSK9 inhibitor should be considered if the LDL-C goal has not been achieved with the maximum tolerated dose of a statin and ezetimibe.	IIa	B
If a patient requires initiation of dialysis therapy, it is recommended to continue their previous therapy with a statin or a statin and ezetimibe.	IIa	C
Initiation of lipid-lowering agents in patients requiring dialysis is not recommended in the absence of atherosclerotic cardiovascular disease.	III	A